In a striking policy reversal, a key CDC advisory panel has voted to end the decades-old recommendation that all newborns receive the hepatitis B vaccine immediately after birth, potentially altering the vaccination timeline for millions of American babies.
The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 8-3 last Friday to recommend delaying the hepatitis B vaccine birth dose for most infants whose mothers tested negative for the virus during pregnancy, overturning a universal vaccination policy that has been in place for 30 years and is credited with dramatically reducing hepatitis B infections.
Instead, the committee now recommends that parents discuss with their doctors whether to administer the hepatitis B vaccine at birth or begin the vaccine series when their baby reaches 2 months of age. The recommendation doesn’t change for babies born to mothers who tested positive for hepatitis B or whose status is unknown — these infants should still receive the vaccine at birth along with hepatitis B immune globulin.
A Major Shift in Prevention Strategy
Why the sudden change? The birth dose policy was originally implemented to create a safety net that would protect as many babies as possible from contracting the virus. This aggressive approach was deemed necessary because an estimated 90% of babies infected in infancy develop chronic hepatitis B infection, which can lead to serious liver disease and premature death from liver cancer or cirrhosis.
The December 2025 ACIP meeting included presentations on vaccine safety, the burden of disease, and perspectives from both vaccine manufacturers and individuals with lived experience. These discussions ultimately led to the committee’s decision to revise the longstanding recommendation.
It’s worth noting that hepatitis B vaccines have proven highly effective, with studies indicating that immunity persists for at least 30 years among healthy people who begin vaccination before 6 months of age.
What Happens Next?
Before this recommendation becomes official CDC policy, it must first be endorsed by Jim O’Neill, the acting director of the Centers for Disease Control and Prevention, or by health secretary Robert F. Kennedy Jr. Only then will it be incorporated into the CDC vaccination schedule.
Currently, the CDC recommends hepatitis B vaccination for all infants at birth, unvaccinated children under 19, adults aged 19–59, and adults 60 and older who have risk factors for hepatitis B or are seeking protection.
The shift represents a significant departure from three decades of public health guidance. Critics worry the change could potentially create gaps in protection, while supporters argue it gives parents more flexibility in vaccination decisions while maintaining protection for those at highest risk.
For now, healthcare providers are likely to continue following existing protocols until official guidance is updated—leaving many new and expectant parents wondering what this means for their newborns in the coming months.
